Topamax® (topiramate): Updated warnings and precautions on visual field defects

Janssen, a division of Johnson & Johnson Pte Ltd, would like to alert healthcare professionals to the potential risk of visual field defects associated with Topamax^®. In double-blind, controlled monotherapy epilepsy trials, visual field defects were reported at a frequency of 0% to 1.3% in Topamax^®-treated adult patients. Based on cumulative data from a recent review of post-marketing safety databases and clinical trials, the package insert for Topamax^® will be updated to reflect new safety information and guidance on visual field defects. Healthcare professionals are advised to consider discontinuing Topamax^® if visual problems occur at any time during treatment with this drug. Please refer to the letter for more information

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of these letters can be found in the MOH Alert System, which is accessible via the Health Professionals Portal (HPP), a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://hpp.moh.gov.sg ↗ (opens in new tab) and follow the procedures below to access the MOH Alert system.

Step 1: Select your profession under ‘For Healthcare Professionals’.

Step 2: Click on ‘Useful links’.

Step 3: Click on ‘MOH Alert’ and log in via Singpass.

Step 4: Click on ‘Drug Alerts’ or ‘Med Device Alerts’ to view the DHCPLs.